Curative Biotechnology, Inc.

Equities

CUBT

US23128N1081

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
0.027 ^USD	-3.57%		+10.66%	+26.76%

2023	Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	CI
2023	Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	CI

Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.

November 25, 2023 at 12:00 am EST

Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.

Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 1,333,333
PriceRange: $6
Discount Per Security: $0.42

Latest news about Curative Biotechnology, Inc.

Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	Nov. 25	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	23-09-07	CI
Curative Biotechnology, Inc. Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions	23-06-07	CI
Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study	23-01-05	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.	22-11-07	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.	22-10-31	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-01	CI
Curative Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-06-29	CI
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors	22-06-16	CI
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors	22-05-12	CI
Curative Biotechnology, Inc. has filed an IPO.	22-04-15	CI
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Curative Biotechnology Announces Cooperative Research and Development Agreement with the National Eye Institute	22-03-21	CI
Curative Biotechnology, Inc. announced that it has received $1 million in funding	22-03-20	CI
Curative Biotechnology, Inc. announced that it expects to receive $1 million in funding	22-03-03	CI
Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular Degeneration	21-11-24	CI
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	21-11-23	CI
Curative Biotechnology, Inc. Appoints Dr. Catherine Sohn as Special Advisor to Board and CEO	21-10-12	CI
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine	21-10-07	CI
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board	21-09-02	CI
Curative Biotechnology, Inc. has Changed its Ticker to CUBT from CTYX	21-04-29	CI
Curative Biotechnology, Inc. Announces Additions to Scientific and Clinical Advisory Board	21-04-29	CI
Connectyx Technologies Holdings Group, Inc. Announces Management Changes	21-02-11	CI
Connectyx Technologies Holdings Group, Inc. Appoints I Richard Garr as Chief Executive Officer	21-02-11	CI

Chart Curative Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURATIVE BIOTECHNOLOGY, INC.	+26.76%	25.29M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research